NEWSnet Portland
    • Homepage
Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy

Author: Solid Biosciences Inc.

Posted Date:

May 8, 2026
  • Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy

    Solid Biosciences Inc.
    May 8, 2026
  • Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Solid Biosciences Inc.
    May 8, 2026
  • Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy

    Solid Biosciences Inc.
    May 7, 2026
  • Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy

    Solid Biosciences Inc.
    May 7, 2026
  • Solid Biosciences to Participate at Upcoming Investor Conferences

    Solid Biosciences Inc.
    May 5, 2026
  • Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

    Solid Biosciences Inc.
    May 3, 2026
  • Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial

    Solid Biosciences Inc.
    May 2, 2026
  • Solid Biosciences Announces Oversubscribed $240 Million Private Placement

    Solid Biosciences Inc.
    May 1, 2026
  • Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

    Solid Biosciences Inc.
    May 1, 2026
  • Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Solid Biosciences Inc.
    April 30, 2026
1 2
Next